<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20060313190006+01'00'</creation_date><modification_date>D:20070829114413+02'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-1-00-129_h_dec_0.pdf</pdf_file></head><body><section><header>i commission of the european communities  brussels, 09/03/2000 c(2000) 576</header></section><section><header>commission decision of 09/03/2000 
 granting the marketing authorization for the medicinal 
  
 product for human use, 
  
 &quot;azopt - brinzolamide&quot; 
 only the english text is authentic.</header><p>ii</p></section><section><header>commission decision of 09/03/2000 
 granting the marketing authorization for the medicinal 
  
 product for human use, 
  
 &quot;azopt - brinzolamide&quot; 
 only the english text is authentic.</header><p>the commission of the european communities,</p><p>having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, and in particular article 10(1) and (2) thereof,</p><p>having regard to the application submitted by alcon laboratories (uk) ltd., on 18 
 december 1998, under article 4(1) of regulation (eec) no 2309/93, concerning the 
 medicinal product, &quot;azopt - brinzolamide&quot;, 
 having regard to the opinion of 18 november 1999 of the european agency for the 
 evaluation of medicinal products, formulated by the committee for proprietary 
 medicinal products,</p><p>
 whereas:</p><p>
 (1)</p><p>the medicinal product, &quot;azopt - brinzolamide &quot;, complies with the requirements 
 of council directives 65/65/eec
 2, 75/318/eec3 and 75/319/eec4, as last amended by directive 93/39/eec
 5;</p><p>
 1 oj no l 214, 24. 8. 1993, p. 1. 2 oj no 22, 9.2.1965, p. 369/65. 3 oj no l 147, 9.6.1975, p. 1. 4 oj no l 147, 9.6.1975, p. 13. 5 oj no l 214, 24.8.1993, p. 22.</p><p> iii(2)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use,</p><p>
 has adopted this decision:</p><p>
 article 1</p><p>the marketing authorization referred to in article 3 of regulation (eec) no 2309/93 is hereby granted in respect of the medicinal product, &quot;azopt - brinzolamide&quot; whose 
 characteristics are summarized in annex i hereto. this medicinal product shall be entered 
 in the community register of medicinal products under the numbers:</p><p>
 eu/1/00/129/001 
 azopt - 10 mg/ml - eye drops, suspension - bottle (ldpe) - 1 bottle 
 (5 ml) - ocular use 
 eu/1/00/129/002 
 azopt - 10 mg/ml - eye drops, suspension - bottle (ldpe) - 1 bottle 
 (10 ml) - ocular use 
 article 2</p><p>the marketing authorization concerning the medicinal product referred to in article 1 shall be subject to compliance with all the conditions, particularly those relating to 
 manufacture and/or importation, control and issue referred to in annex ii.</p><p>
 article 3</p><p>the labelling and package leaflet concerning the medicinal product referred to in article 1 shall conform to annex iii.</p><p>
 article 4</p><p>the period of validity of the authorization issued shall be five years from the date of notification of this decision. it shall be renewable under the conditions laid down in 
 article 13(1) of regulation (eec) no 2309/93.</p><p>
 article 5</p><p>this decision is addressed to alcon laboratories (uk) ltd., boundary way, hemel hempstead, herts hp2 7ud, united kingdom.</p><p>
 done at brussels, 09/03/2000 
 for the commission erkki liikanen 
 member of the commision</p></section></body></xml>